Rapt Therapeutics Reports the P-II Study Results of Tivumecirnon Plus Keytruda for Treating Head and Neck Cancer
Shots:
- The company has reported data from advanced head & neck squamous cell carcinoma (HNSCC) CPI-experienced patient’s arm of the P-I/II dose escalation & expansion trial assessing the safety & preliminary anti-tumor activity of tivumecirnon alone & combined with Keytruda for various Treg & CCR4 pathway-enriched tumors in the US, Australia & Asia
- The study, in CPI-experienced HNSCC patients (n=32), demonstrated a confirmed ORR of 15.6% in 5/32 patients irrespective of PD-L1 or HPV status, 17.4% in 4/23 of them with PD-L1+ disease and 22.2% in 4/18 of them with HPV+ disease. Results were highlighted at the AACR
- Tivumecirnon is a small molecule antagonist that targets CCR4 to block the regulatory T cells’ migration into the tumor cells and not into the healthy tissues
Ref: RAPT Therapeutics | Image: RAPT Therapeutics
Related News:- The US FDA Places Clinical Hold on the Trials Assessing RAPT Therapeutics’ Zelnecirnon
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
